Literature DB >> 18583566

A review of transfusion practice before, during, and after hematopoietic progenitor cell transplantation.

James L Gajewski1, Viviana V Johnson, S Gerald Sandler, Antoine Sayegh, Thomas R Klumpp.   

Abstract

The increased use of hematopoietic progenitor cell (HPC) transplantation has implications and consequences for transfusion services: not only in hospitals where HPC transplantations are performed, but also in hospitals that do not perform HPC transplantations but manage patients before or after transplantation. Candidates for HPC transplantation have specific and specialized transfusion requirements before, during, and after transplantation that are necessary to avert the adverse consequences of alloimmunization to human leukocyte antigens, immunohematologic consequences of ABO-mismatched transplantations, or immunosuppression. Decisions concerning blood transfusions during any of these times may compromise the outcome of an otherwise successful transplantation. Years after an HPC transplantation, and even during clinical remission, recipients may continue to be immunosuppressed and may have critically important, special transfusion requirements. Without a thorough understanding of these special requirements, provision of compatible blood components may be delayed and often urgent transfusion needs prohibit appropriate consultation with the patient's transplantation specialist. To optimize the relevance of issues and communication between clinical hematologists, transplantation physicians, and transfusion medicine physicians, the data and opinions presented in this review are organized by sequence of patient presentation, namely, before, during, and after transplantation.

Entities:  

Mesh:

Year:  2008        PMID: 18583566      PMCID: PMC2569162          DOI: 10.1182/blood-2007-10-118372

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  88 in total

1.  Comparison of COBE Spectra software version 4.7 PBSC and version 6.0 auto PBSC program.

Authors:  R Wilke; M Brettell; H M Prince; M Wolf; R McKenna; E Serpell; M Molloy; H Stevens; M Quinn; P Gates; P Chapple
Journal:  J Clin Apher       Date:  1999       Impact factor: 2.821

2.  ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation.

Authors:  R J Benjamin; S McGurk; M S Ralston; W H Churchill; J H Antin
Journal:  Transfusion       Date:  1999-02       Impact factor: 3.157

3.  Risk factors for severe hemorrhagic cystitis following BMT.

Authors:  A Seber; X O Shu; T Defor; S Sencer; N Ramsay
Journal:  Bone Marrow Transplant       Date:  1999-01       Impact factor: 5.483

Review 4.  Volume-reduced platelet concentrates.

Authors:  Helge Schoenfeld; Claudia Spies; Christian Jakob
Journal:  Curr Hematol Rep       Date:  2006-03

5.  Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: frequent long-term microchimerism in severe trauma patients.

Authors:  T H Lee; T Paglieroni; H Ohto; P V Holland; M P Busch
Journal:  Blood       Date:  1999-05-01       Impact factor: 22.113

6.  ABO blood group barrier in allogeneic bone marrow transplantation revisited.

Authors:  Jörg D Seebach; Georg Stussi; Jakob R Passweg; Fausto R Loberiza; James L Gajewski; Armand Keating; Martin Goerner; Philip A Rowlings; Pierre Tiberghien; Gerald J Elfenbein; Robert Peter Gale; Jon J van Rood; Vijay Reddy; Eliane Gluckman; Brian J Bolwell; Thomas R Klumpp; Mary M Horowitz; Olle Ringdén; A John Barrett
Journal:  Biol Blood Marrow Transplant       Date:  2005-12       Impact factor: 5.742

7.  Clinical consequences of alterations in platelet transfusion dose: a prospective, randomized, double-blind trial.

Authors:  T R Klumpp; J H Herman; J P Gaughan; R R Russo; R A Christman; S L Goldberg; S J Ackerman; G C Bleecker; K F Mangan
Journal:  Transfusion       Date:  1999-07       Impact factor: 3.157

8.  Anti-D alloimmunization after D-mismatched allogeneic hematopoietic stem cell transplantation in patients with hematologic diseases.

Authors:  Joan Cid; Miguel Lozano; Francesc Fernández-Avilés; Enric Carreras; Arturo Pereira; Roberto Mazzara; Antorio Ordinas
Journal:  Transfusion       Date:  2006-02       Impact factor: 3.157

9.  Multiple red cell alloantibodies, including anti-Dib, after allogeneic ABO-matched peripheral blood progenitor cell transplantation.

Authors:  Barbara Zupańska; J Maciej Zaucha; Bogumila Michalewska; Aniela Malinowska; Ewa Brojer; Andrzej Hellmann
Journal:  Transfusion       Date:  2005-01       Impact factor: 3.157

10.  Implementation of peripheral blood CD34 analyses to initiate leukapheresis: marked reduction in resource utilization.

Authors:  Kenneth R Meehan; John M Hill; Linda Patchett; Susan M Webber; Jillian Wu; Pamela Ely; Zbigniew M Szczepiorkowski
Journal:  Transfusion       Date:  2006-04       Impact factor: 3.157

View more
  20 in total

Review 1.  Anemia of Central Origin.

Authors:  Kazusa Ishii; Neal S Young
Journal:  Semin Hematol       Date:  2015-07-09       Impact factor: 3.851

Review 2.  Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Authors:  Malte Ziemann; Holger Hennig
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

3.  GM-CSF and IL-4 Fusion Cytokine Induces B Cell-Dependent Hematopoietic Regeneration.

Authors:  Jiusheng Deng; Yanqiu Li; Andrea Pennati; Shala Yuan; Jian Hui Wu; Edmund K Waller; Jacques Galipeau
Journal:  Mol Ther       Date:  2017-02-01       Impact factor: 11.454

4.  Is surgical volume still the most accurate indicator of blood usage in the United States?

Authors:  Alexandra Savinkina; Mathew R P Sapiano; James Berger; Sridhar V Basavaraju
Journal:  Transfusion       Date:  2019-02-10       Impact factor: 3.157

Review 5.  Indications for platelet transfusion in patients with thrombocytopenia.

Authors:  Jerry E Squires
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

6.  Platelet and red blood cell utilization and transfusion independence in umbilical cord blood and allogeneic peripheral blood hematopoietic cell transplants.

Authors:  Melhem Solh; Claudio Brunstein; Shanna Morgan; Daniel Weisdorf
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-14       Impact factor: 5.742

Review 7.  Donor selection in T cell-replete haploidentical hematopoietic stem cell transplantation: knowns, unknowns, and controversies.

Authors:  Stefan O Ciurea; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2012-08-11       Impact factor: 5.742

Review 8.  Platelet transfusion refractoriness: how do I diagnose and manage?

Authors:  Claudia S Cohn
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

9.  Integration of red cell genotyping into the blood supply chain: a population-based study.

Authors:  Willy A Flegel; Jerome L Gottschall; Gregory A Denomme
Journal:  Lancet Haematol       Date:  2015-07       Impact factor: 18.959

10.  ABO chimerism determined by real-time polymerase chain reaction analysis after ABO-incompatible haematopoietic stem cell transplantation.

Authors:  Feng Liu; Guining Li; Xiaolu Mao; Lihua Hu
Journal:  Blood Transfus       Date:  2012-07-04       Impact factor: 3.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.